Richard Adcock compensation by year
ImmunityBio Summary Compensation Table · all 6 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $141,347 | $765,144 | $790,760 | $796,000 | $802,123 | $831,667 |
| Bonus | $67,808 | $57,656 | $0 | $298,500 | $0 | $141,684 |
| Stock awards | $0 | $13,872,641 | $0 | $0 | $2,396,341 | $2,787,828 |
| Option awards | $0 | $13,969,483 | $3,159,057 | $0 | $7,214,767 | $8,353,406 |
| Non-equity incentive | $0 | $269,063 | $0 | $0 | $477,600 | $485,166 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $1,731 | $82,740 | $58,690 | $62,403 | $64,044 | $117,202 |
| Total | $210,886 | $29,016,727 | $4,008,507 | $1,156,903 | $10,954,875 | $12,716,953 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ImmunityBio, Inc. DEF 14A filed April 30, 2026, accession 0001326110-26-000049, and prior-year filings.
How this page was built: the ImmunityBio, Inc. filed document, accession 0001326110-26-000049. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 822,368 | $1,628,289 | — |
| RSU | 304,878 | $603,658 | — |
| RSU | 51,731 | $102,427 | — |
| Option | 2,812,500 | — | $3.39 |
| Option | 1,060,976 | — | $5.24 |
Per the Outstanding Equity Awards at Fiscal Year-End table in ImmunityBio, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments ImmunityBio discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Resignation for good reason, no change in control | — | — | — | $0 |
| Involuntary termination without cause | $835,800 | — | — | $835,800 |
Per the Potential Payments Upon Termination or Change in Control table in ImmunityBio, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
ImmunityBio’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Richard Adcock · this page | President and CEO | $12,716,953 |
| Patrick Soon-Shiong | Founder, Executive Chairman of the Board and Global Chief Scientific and Medical Officer | $12,293,255 |
| David Sachs | CFO | $4,244,543 |
| Regan Lauer | Chief Accounting Officer | $745,313 |
Board service
ImmunityBio board · FY2021–FY2025How this board is paid
Company policy: ImmunityBio pays directors a $50,000 cash retainer and $400,000 in Options. As stated in ImmunityBio's FY2025 proxy.
The full ImmunityBio compensation record
free company briefThis page is one person within ImmunityBio's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the ImmunityBio proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order ImmunityBio's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ImmunityBio's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.